Technology ID
TAB-4851
Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening
E-Numbers
E-033-2014-0
Lead Inventor
Collins, Peter (NIAID)
Co-Inventors
Buchholz, Ursula (NIAID)
Biacchesi, Stephanie (Institut national de la recherche agronomique (INRA))
Applications
Diagnostics
Therapeutic Areas
Respiratory
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Research Equipment
Plasmids/Vectors
Lead IC
NIAID
ICs
NIAID
The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral interventions.
Commercial Applications
Incorporating enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers versatile applications, including virology research for infection mechanisms, high-throughput drug screening, sensitive diagnostics, and vaccine development.
Competitive Advantages
The incorporation of enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers a competitive advantage by providing a precise and rapid method for monitoring virus infection. This technology enables real-time visualization, simplifies high-throughput screening for potential antiviral agents, and streamlines viral particle quantification through GFP-based assays. Its sensitivity and efficiency make it a valuable tool for advancing virology research and expediting antiviral drug discovery.
Licensing Contact: